Advancing Purification for Complex Biologics
At ChromaGenix™, we help biopharma innovators overcome some of the most persistent challenges in drug development: how to purify complex biologics such as AAVs, mRNA, and viral vectors, more efficiently, consistently, and at scale.
We specialize in developing synthetic affinity ligands and chromatography resins that are engineered for the production of advanced therapies. Whether you’re working on gene therapy, vaccines, or emerging modalities, ChromaGenix is committed to solving your critical downstream challenges, backed by a culture of innovation, integrity, and scientific rigor.
Purification Technologies for the Next Era of Biomanufacturing
ChromaGenix combines proven purification chemistry with investment, a new GMP facility, and a growing portfolio of high-performance tools. We also maintain a deep research partnership with NC State University for the ongoing development of novel, peptide-based affinity ligands to meet the evolving demands of modern bioprocessing.
